197 related articles for article (PubMed ID: 38393520)
1. Exploring the potential of EphA2 receptor signaling pathway: a comprehensive review in cancer treatment.
Nehal M; Khatoon J; Akhtar S; Khan MKA
Mol Biol Rep; 2024 Feb; 51(1):337. PubMed ID: 38393520
[TBL] [Abstract][Full Text] [Related]
2. Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer.
Gökmen-Polar Y; Toroni RA; Hocevar BA; Badve S; Zhao Q; Shen C; Bruckheimer E; Kinch MS; Miller KD
Breast Cancer Res Treat; 2011 Jun; 127(2):375-84. PubMed ID: 20602165
[TBL] [Abstract][Full Text] [Related]
3. The Functions of EphA1 Receptor Tyrosine Kinase in Several Tumors.
Wu Y; Du Z; Mou J; Qiu X; Chen J; Cai S; Ren D; Xiao F; Zhou G; Yuan C
Curr Med Chem; 2023; 30(20):2340-2353. PubMed ID: 35996244
[TBL] [Abstract][Full Text] [Related]
4. EphA2 signaling following endocytosis: role of Tiam1.
Boissier P; Chen J; Huynh-Do U
Traffic; 2013 Dec; 14(12):1255-71. PubMed ID: 24112471
[TBL] [Abstract][Full Text] [Related]
5. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization.
Ogawa K; Pasqualini R; Lindberg RA; Kain R; Freeman AL; Pasquale EB
Oncogene; 2000 Dec; 19(52):6043-52. PubMed ID: 11146556
[TBL] [Abstract][Full Text] [Related]
6. Ephrin-A1 inhibits NSCLC tumor growth via induction of Cdx-2 a tumor suppressor gene.
Sukka-Ganesh B; Mohammed KA; Kaye F; Goldberg EP; Nasreen N
BMC Cancer; 2012 Jul; 12():309. PubMed ID: 22824143
[TBL] [Abstract][Full Text] [Related]
7. Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells.
Yang NY; Fernandez C; Richter M; Xiao Z; Valencia F; Tice DA; Pasquale EB
Cell Signal; 2011 Jan; 23(1):201-12. PubMed ID: 20837138
[TBL] [Abstract][Full Text] [Related]
8. EphA2: A promising therapeutic target in breast cancer.
Zhao P; Jiang D; Huang Y; Chen C
J Genet Genomics; 2021 Apr; 48(4):261-267. PubMed ID: 33962882
[TBL] [Abstract][Full Text] [Related]
9. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.
Wykosky J; Debinski W
Mol Cancer Res; 2008 Dec; 6(12):1795-806. PubMed ID: 19074825
[TBL] [Abstract][Full Text] [Related]
10. Exosomal EPHA2 derived from highly metastatic breast cancer cells promotes angiogenesis by activating the AMPK signaling pathway through Ephrin A1-EPHA2 forward signaling.
Han B; Zhang H; Tian R; Liu H; Wang Z; Wang Z; Tian J; Cui Y; Ren S; Zuo X; Tian R; Niu R; Zhang F
Theranostics; 2022; 12(9):4127-4146. PubMed ID: 35673569
[No Abstract] [Full Text] [Related]
11. An ephrin mimetic peptide that selectively targets the EphA2 receptor.
Koolpe M; Dail M; Pasquale EB
J Biol Chem; 2002 Dec; 277(49):46974-9. PubMed ID: 12351647
[TBL] [Abstract][Full Text] [Related]
12. Biological and structural characterization of glycosylation on ephrin-A1, a preferred ligand for EphA2 receptor tyrosine kinase.
Ferluga S; Hantgan R; Goldgur Y; Himanen JP; Nikolov DB; Debinski W
J Biol Chem; 2013 Jun; 288(25):18448-57. PubMed ID: 23661698
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic functions and therapeutic targeting of EphA2 in cancer.
Wilson K; Shiuan E; Brantley-Sieders DM
Oncogene; 2021 Apr; 40(14):2483-2495. PubMed ID: 33686241
[TBL] [Abstract][Full Text] [Related]
14. Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis.
Nakamoto M; Bergemann AD
Microsc Res Tech; 2002 Oct; 59(1):58-67. PubMed ID: 12242697
[TBL] [Abstract][Full Text] [Related]
15. A paradigm shift in EPH receptor interaction: biological relevance of EPHB6 interaction with EPHA2 and EPHB2 in breast carcinoma cell lines.
Fox BP; Kandpal RP
Cancer Genomics Proteomics; 2011; 8(4):185-93. PubMed ID: 21737611
[TBL] [Abstract][Full Text] [Related]
16. Attenuation of eph receptor kinase activation in cancer cells by coexpressed ephrin ligands.
Falivelli G; Lisabeth EM; Rubio de la Torre E; Perez-Tenorio G; Tosato G; Salvucci O; Pasquale EB
PLoS One; 2013; 8(11):e81445. PubMed ID: 24348920
[TBL] [Abstract][Full Text] [Related]
17. EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics.
Ireton RC; Chen J
Curr Cancer Drug Targets; 2005 May; 5(3):149-57. PubMed ID: 15892616
[TBL] [Abstract][Full Text] [Related]
18. EphA2-induced angiogenesis in ewing sarcoma cells works through bFGF production and is dependent on caveolin-1.
Sáinz-Jaspeado M; Huertas-Martinez J; Lagares-Tena L; Martin Liberal J; Mateo-Lozano S; de Alava E; de Torres C; Mora J; Del Muro XG; Tirado OM
PLoS One; 2013; 8(8):e71449. PubMed ID: 23951165
[TBL] [Abstract][Full Text] [Related]
19. EphA2-dependent molecular targeting therapy for malignant tumors.
Biao-xue R; Xi-guang C; Shuan-ying Y; Wei L; Zong-juan M
Curr Cancer Drug Targets; 2011 Nov; 11(9):1082-97. PubMed ID: 21933105
[TBL] [Abstract][Full Text] [Related]
20. Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer.
Chang Q; Jorgensen C; Pawson T; Hedley DW
Br J Cancer; 2008 Oct; 99(7):1074-82. PubMed ID: 18797457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
